CUMBERLAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
| Cumberland Pharmaceuticals Inc. Shareholders | |||||
|---|---|---|---|---|---|
| Common stock · Accumulated deficit · Non-controlling interest · Total equity | |||||
| Shares · Amount | |||||
| Balance, December 31, 2023 | 14,121,833 | $47,091,602 | $(17,488,161) | $(343,572) | $29,259,869 |
| Net loss | — | — | (6,479,770) | 36,055 | (6,443,715) |
| Share-based compensation | 169,991 | 301,895 | — | — | 301,895 |
| Repurchase of common shares | (339,200) | (572,072) | — | — | (572,072) |
| Balance, December 31, 2024 | 13,952,624 | $46,821,425 | $(23,967,931) | $(307,517) | $22,545,977 |
| Net loss | — | — | (2,836,128) | (28,583) | (2,864,711) |
| Proceeds from the sale of common stock, net of offering costs | 1,000,000 | 4,715,950 | — | — | 4,715,950 |
| Share-based compensation | 62,950 | 408,320 | — | — | 408,320 |
| Repurchase of common shares | (58,947) | (261,314) | — | — | (261,314) |
| Balance, December 31, 2025 | 14,956,627 | $51,684,381 | $(26,804,059) | $(336,100) | $24,544,222 |
See accompanying notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.